Fast Market Research

"Chronic Pain - Pipeline Review, H1 2014" Published

New Pharmaceuticals research report from Global Markets Direct is now available from Fast Market Research


Boston, MA -- (SBWIRE) -- 05/21/2014 -- Chronic Pain - Pipeline Review, H1 2014


Global Markets Direct's, 'Chronic Pain - Pipeline Review, H1 2014', provides an overview of the Chronic Pain's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chronic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Pain and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

View Full Report Details and Table of Contents

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- The report provides a snapshot of the global therapeutic landscape of Chronic Pain
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Chronic Pain and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Chronic Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects

Companies Mentioned in this Report: DURECT Corporation, Johnson & Johnson, Allergan, Inc., UMeWorld Limited, Sanofi, AstraZeneca PLC, Eli Lilly and Company, Nektar Therapeutics, Daiichi Sankyo Company, Limited, Merck & Co., Inc., Santen Pharmaceutical Co., Ltd., Daewoong Pharmaceutical Co., Ltd., Laboratorios Del Dr. Esteve S.A., Glenmark Pharmaceuticals Ltd., Nippon Shinyaku Co., Ltd., Orion Oyj, Pain Therapeutics, Inc., Pfizer Inc., Purdue Pharma L.P., Teva Pharmaceutical Industries Limited, Collegium Pharmaceutical, Inc., Benitec Biopharma Limited, Bionomics Limited, Acadia Pharmaceuticals Inc., Elite Pharmaceuticals, Inc., Zalicus Inc., Hisamitsu Pharmaceutical Co., Inc., Pozen, Inc., Mertiva AB, tesa Labtec GmbH, Debiopharm International S.A., Insys Therapeutics, Inc., Chromocell Corporation, Immupharma Plc, Phosphagenics Limited, Grunenthal GmbH, CoLucid Pharmaceuticals, Inc., Trevena, Inc., Syntrix Biosystems, Inc., Kineta, Inc., Concert Pharmaceuticals, Inc., QRxPharma Limited, Cara Therapeutics, Inc., arGEN-X BV, Endo Pharmaceuticals Inc., Sorrento Therapeutics, Inc., Relmada Therapeutics, Inc., Afferent Pharmaceuticals, Inc., St. Charles Pharmaceuticals, Convergence Pharmaceuticals Ltd., Adynxx, Inc., Kareus Therapeutics, SA, Signature Therapeutics, Inc, Recro Pharma, Inc., Creabilis SA, Neura Therapeutik, LLC, AbbVie Inc., Nanomerics Ltd, ChironWells GmbH, Akron Molecules GmbH, GlobalAcorn

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Chronic Back Pain - Pipeline Review, H1 2014
- Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014
- Neuropathic Pain - Pipeline Review, H1 2014
- Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H1 2014
- Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H1 2014
- Inflammatory Pain - Pipeline Review, H1 2014
- Cancer Pain - Pipeline Review, H1 2014
- Acute Pain - Pipeline Review, H1 2014
- Osteoarthritis Pain - Pipeline Review, H1 2014
- Chronic Heart Failure - Pipeline Review, H1 2014